Registration Desk Open

GUSIG Meeting

NZACS Meeting

Joint Sessions with NZ Cancer Nurses

Registration desk open 

Conference Welcome

Chair: David Hamilton 
Hedgehog signalling, innate chemoresistance
and tumor regeneration
 Dr Neil Watkins
Kindly sponsoreed by the Cancer Society of New Zealand, Wellington Division Inc

Targeting human growth hormone; a radiosensitising strategy
Dr Jo Perry 

The in vitro development of triple-negative (ER- PR- HER2-)
variants of the ER+ MCF7 breast cancer line
Dr Euphemia Leung

Morning Tea amongst sponsors and exhibitors

Chair: Lai-Ming Ching
 Manipulating immunity
Associate Professor Phil Darcy 
Kindly sponsored by the Malaghan Institute

A phase I trial of dendritic cell vaccination and temozolomide
 for recurrent glioblastoma multiforme 
Dr Martin Hunn

Dr Catherine Barrow

             
Dr Rob Weinkove

Lunch amongst sponsors and exhibitors
Kindly sponsored by Novartis Oncology

1.00pm

Bruce Cain Memorial Lecture
Chair: Michael Jameson
Bruce Cain; the legacy. Cancer drug development in the Auckland Cancer Society Research Centre
           Professor Bill Denny            

2.00pm

The unlevel playing field: ethnic inequalities in cancer outcomes in New Zealand
Dr Diana Sarfati

Colorectal Cancer in New Zealand – stuck at the bottom of the world?
Dr Chris Jackson

Assessment of older patients for risk of chemotherapy toxicity 
 Nadia Schwass

 A booklet on participant's rights to improve consent for clinical research: a randomized trial
Jocelyne Benatar

Afternoon Tea amongst sponsors and exhibitors
Kindly sponsored by Novartis Oncology

Chair: Parry Guilford
Dr Jeroen Douwes

Gut bacteria: a cause of cancer?
Dr Jacquie Keenan

Poster Presentations

Living conditions of cancer cells and the neighbourhood
Lynn Murray

Mouse immunotherapy models for haematological malignancies in the central nervous system
Carole Grasso

Identification of markers that affect the function of cytotoxic T lymphocytes in anti-tumor immunotherapy
Shujie He

HIgh dose ascorbate kills cancer cells in more ways than one
Dr Patries Herst

Post-treatment quality-of-life of head and neck cancer patients treated with IMRT - Waikato Hospital Experience
Shibu Joseph

SHON is oncogenice in human mammary carcinoma
Yewon Jung

Identification and validation of potential protein biomarkers for predicting colorectal cancer spread
Chandra Kirana

Chromosome banding patterns and association of drug metabolizing gene (GST and CYP), P53 codon 72 polymorphism in chronic myeloid leukemic patients in South Indian population
S Ahamed Mustaq

Correlation between tumour necrosis and overall survival in adult osteosarcoma treated with neoadjuvant cisplatin and doxorubicin
Gareth Rivalland

Chromosomal aberrations found among hepatocellular carcinoma patients in coimbatore population
Kesavarao Sasikala

Proteomic identification and immunological validation of potential novel early detection markers for colorectal cancer
Shi, Hongjun

 NZSO AGM

Conference Dinner at Macs Brew Bar, Wellington Waterfront

Registration desk open 

 Eli Lilly Award Presentations

CD8αα+ langerin+ Dendritic Cells Maintain Effector CD8 T Cells After Adoptive Tran
John Gibbins

An audit of cisplatin and vinorelbine use and tolerability for patients receiving adjuvant treatment of non-small cell lung cancer
Abbey Jebb

Peritumoral treatments with poly I:C or MSU + M. smegmatis enhance the anti-tumour response by activating both innate and adaptive immunity
Sabine Kuhn

Combining the toll-like receptor agonists Pam3Cys and Poly I:C enhances Flt3L dendritic cell activation for cancer immunotherapy
So Nai Lim

Proteomic Identification and Immunological Validation of Protein Biomarkers for Early Detection and Prognosis of Colorectal Cancer
Hongjung Shi

 Increased regulatory and inflammatory T cells and decreased effector T cells in colorectal cancer tumour and isolation of functional T cell subsets
Edward Taylor

Kindly sponsored by Eli Lily

Morning Tea amongst sponsors and exhibitors
Kindly sponsored by Novartis Oncology

 Chair: Bridget Robinson
            The Auckland melanoma experience
Dr Mike McCrystal

Progress and Pitfalls in the establishment of a Renal Cell Carcinoma (RCC) research program in New Zealand
Reuben Broom

Bone Morphogenetic Protein 4 (BMP4) suppresses breast cancer metastasis
Professor Robin Anderson
Kindly sponsored by the Maurice Wilkins Centre

Defining mechanisms underlying breast cancer metastasis to brain
Dr Jodi Saunus 

Audit of patients with asymptomatic brain metastases in BIBF trial and review of literature
Gareth Rivalland 

Phenotype of mouse embryonic fibroblasts expressing single VEGF isoforms
Dr Gabi Dachs

Lunch amongst sponsors and exhibitors
Kindly sponsored by Novartis Oncology

Presentaion of awards

Chair: Nuala Helsby  
PAX genes and their role in cancer – an update
Prof Mike Eccles

Bioinformatics identifies biomarkers for E2F1-driven cellular proliferation pathways in breast cancer and melanoma
Cristin Print

Prognostic breast cancer risk markers using a FISH mini array 
Paul Oei

2.30pm

 Do Multidrug Resistance Mechanisms Enhance the Action of the Anticancer Drug SN 28049?
Prof Bruce Baguley

Intracellular ascorbate, HIF-1 inhibition and effect on tumour growth
Assoc Prof Margreet Vissers

Differential Expression of Heterochromatin Protein 1 in Tumours
Tracy Hale

Afternoon Tea amongst sponsors and exhibitors

Chair: Michael Berridge
Two anti-cancer agents based on inhibition of nucleoside salvage enzymes
Dr Richard Furneaux

Development of enzymes that co-metabolise prodrugs and PET probes for anti-cancer gene therapy
Dr David Ackerley

Use of IVIS optical imager to monitor activity of novel anti-vascular therapies on subcutaneous or intracranial GL261 - luciferase glioblastoma cells in mice
Ching, Lai Ming

Close of meeting